Aspirin News and Research

RSS

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.

Rapamycin is more effective at slowing down aging, says researcher

The scientist discusses several reasons, including fear of the actual and fictional side effects of rapamycin, everolimus and other clinically-approved drugs, arguing that no real side effects preclude their use as anti-aging drugs today.

17 Oct 2019

Osteoarthritis has no cure, but symptoms can be managed

Osteoarthritis can't be ignored. On a grand scale, it is the most common form of arthritis (which actually isn't a specific disease but rather a general term for inflammation in a joint), accounting for more cases than all the other forms combined. It affects an estimated 31 million Americans and is a leading cause of disability among adults.

10 Oct 2019

Aspirin may reduce adverse effects of air pollution exposure on lung function

A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs like aspirin may lessen the adverse effects of air pollution exposure on lung function.

3 Oct 2019

Study: Aspirin is not recommended for people who never had a heart attack or stroke

If you've never had a heart attack or stroke, you likely should not be taking aspirin to prevent them, according to new research.

3 Oct 2019

Polymer drug-eluting and polymer-free drug-coated stents safe and effective for patients with high bleeding risk

The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.

27 Sep 2019

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

New data from the randomized, placebo-controlled TWILIGHT trial found that compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial infarction, or stroke in high-risk patients who have undergone successful percutaneous coronary intervention and completed three months of dual antiplatelet therapy.

27 Sep 2019

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding risk patients treated with a contemporary drug-eluting stent.

27 Sep 2019

High-risk heart patients may not require long-term aspirin use after stent placement

High-risk patients undergoing coronary stent procedures may not require long-term aspirin use after stent placement, Mount Sinai researchers report in a groundbreaking study

26 Sep 2019

Study highlights need to educate women and medical community about risk factors of preeclampsia

Despite its crowded healthcare market and strong efforts to make healthcare more accessible to patients, New Jersey has one of the highest maternal mortality rates in the nation-;an issue so pertinent that First Lady Tammy Murphy created the Nurture NJ initiative to help reduce infant and maternal mortality.

20 Sep 2019

Low-dose aspirin may improve survival in patients with head and neck, lung cancers

What if a drug that sits in nearly everyone's medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting in Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing treatment for some head/neck and lung cancers.

19 Sep 2019

Roswell Park moving three-pronged immunotherapy strategy forward with support from DoD grant

A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a U.S. Department of Defense grant to Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Rustum Family Professor for Molecular Therapeutics and Translational Research at the Buffalo, N.Y.-based cancer center.

18 Sep 2019

Rutgers cardiologist recommends individualized treatment with aspirin for primary prevention of CVD

A nationally recognized Rutgers cardiologist recommends that aspirin be used as primary prevention for cardiovascular disease only with select patients, saying that the scientific evidence is too diverse to support a one-size-fits-all approach.

17 Sep 2019

Nano-sized bubbles in our body could effectively fight cancer

Healthy cells in our body release nano-sized bubbles that transfer genetic material such as DNA and RNA to other cells. It's your DNA that stores the important information necessary for RNA to produce proteins and make sure they act accordingly.

15 Sep 2019

Benefits of restarting blood thinners outweigh the gastrointestinal‐related risks

Anticoagulants and antiplatelet drugs, which are blood thinners such as warfarin and aspirin, are commonly taken to reduce the risk of potentially fatal blood clots, but they carry an increased risk of gastrointestinal bleeding.

6 Sep 2019

New polypill cheaper, better at reducing cardiovascular disease

A new study from Beth Israel Deaconess Medical Center (BIDMC) has proved the cost-effectiveness and life-saving potential of the “polypill”: a single new pill which combines four commonly prescribed cardiovascular drugs into one to prevent a recurrent stroke or heart event in adult patients in low- and middle-income countries (LMIC).

5 Sep 2019

Edoxaban-based dual therapy noninferior to standard treatment in atrial fibrillation post-stenting

Edoxaban in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting.

4 Sep 2019

Using mesoporous materials as nanovehicle for improved drug delivery

In a paper to be published in the forthcoming issue in NANO, a group of researchers from Guiyang, China, have conducted a study based on previous experimental research on DOX as a model drug and introduced a reverse method in which organic groups are grafted after removing the template agent.

3 Sep 2019

Ticagrelor reduces heart attacks and strokes for patients with diabetes

In late-breaking clinical trial results presented in a Hot Line Session today at the European Society of Cardiology Congress 2019, investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study, a clinical trial sponsored by AstraZeneca that evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary artery disease and diabetes mellitus but without a history of heart attack or stroke.

3 Sep 2019

Shopping at the Apotheke: Compare German pharmacies with your corner drugstore

If you're looking for bobby pins, cheap lipstick or a protein bar, well, sorry, Americans, the German pharmacy can't help you.

30 Aug 2019

MUSC researchers narrow down risk of preeclampsia to a specific phenotype

The force of blood traveling through your arteries and veins determines much of your heart health. High blood pressure can lead to heart disease, heart failure, heart attack, stroke and chronic kidney disease, and when it's coupled with type 1 diabetes and pregnancy, it can put both the mother and the baby at risk.

29 Aug 2019

Aspirin News and Research

Further Reading

Rapamycin is more effective at slowing down aging, says researcher

Osteoarthritis has no cure, but symptoms can be managed

Aspirin may reduce adverse effects of air pollution exposure on lung function

Study: Aspirin is not recommended for people who never had a heart attack or stroke

Polymer drug-eluting and polymer-free drug-coated stents safe and effective for patients with high bleeding risk

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

High-risk heart patients may not require long-term aspirin use after stent placement

Study highlights need to educate women and medical community about risk factors of preeclampsia

Low-dose aspirin may improve survival in patients with head and neck, lung cancers

Roswell Park moving three-pronged immunotherapy strategy forward with support from DoD grant

Rutgers cardiologist recommends individualized treatment with aspirin for primary prevention of CVD

Nano-sized bubbles in our body could effectively fight cancer

Benefits of restarting blood thinners outweigh the gastrointestinal‐related risks

New polypill cheaper, better at reducing cardiovascular disease

Edoxaban-based dual therapy noninferior to standard treatment in atrial fibrillation post-stenting

Using mesoporous materials as nanovehicle for improved drug delivery

Ticagrelor reduces heart attacks and strokes for patients with diabetes

Shopping at the Apotheke: Compare German pharmacies with your corner drugstore

MUSC researchers narrow down risk of preeclampsia to a specific phenotype

Impacts of Neurofeedback Therapy on Neurodegenerative Disorders

Making Sample Management in a Laboratory Digital

How Is Ophthalmology Changing To Meet New Challenges?

Latest News